ClinicalTrials.gg
CompletedNCT04211389DERMIS-2Updated Dec 7, 2022Results posted

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

A Phase 3 interventional study of ARQ-151 0.3% cream and ARQ-151 vehicle cream in Chronic Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 39 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2022-12-07.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.

Enrollment
Largest of 17
442 · median 46
Started
2019
with 1 other
Phase 3
5 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
9 of 17
Arcutis Biotherapeutics, Inc.

Among the 17 studies testing roflumilast in Psoriasis, this one has the largest enrollment, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing roflumilast in Psoriasis, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day for 56 days by subjects with chronic plaque psoriasis

Read the detailed description

This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily x 8 weeks to subjects with psoriasis

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants legally competent to sign and give informed consented and if appropriate assent as required by local laws
  • Males and females ages 2 years and older (inclusive)
  • Clinical diagnosis of psoriasis vulgaris of at least 6 months duration (3 months for children) as determined by the Investigator
  • Females of (FOCBP) must have a negative pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective throughout the trial.
  • In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.
  • Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.

    • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
    • Previous treatment with ARQ-151 or its active ingredient
    • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
    • Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of product
    • Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
442 participants (actual)

Study arms

  • Active comparator
    ARQ-151 cream 0.3%

    Active comparator

    Drug: ARQ-151 0.3% cream

  • Placebo comparator
    ARQ-151 cream vehicle

    Placebo comparator

    Drug: ARQ-151 vehicle cream

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale

    The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.

    Time frame: Week 8

Secondary outcomes

  1. Time to Achieve Psoriasis Area Severity Index-50 (PASI-50)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The time to achieve PASI-50 (defined as a 50% reduction from baseline in PASI score) is presented, and is based on observed data only. Participants are included whether they achieved PASI-50 or not.

    Time frame: From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 124 days)

  2. Number of Participants Achieving Psoriasis Area Severity Index-75 (PASI-75)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

  3. Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

    Time frame: Baseline (Day 1) and Week 8

  4. Number of Participants Achieving Success in Intertriginous Investigator Global Assessment (I-IGA) Scale Assessment of Disease Severity at Week 8

    The number of participants with I-IGA score ≥2 at baseline achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an I-IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline I-IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.

    Time frame: Week 8

  5. Number of Participants Achieving I-IGA Score of 'Clear' at Week 8

    The number of participants achieving an IGA score of 0 ('clear') at Week 8 is presented (observed data only) for each arm. The I-IGA is a 5-point scale assessing the severity of intertriginous area plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.

    Time frame: Week 8

  6. Number of Participants Achieving Success in Worst Itch Numerical Rating Scale (WI-NRS) Pruritus Score

    The number of participants achieving success in WI-NRS is presented. Success is defined as achievement of a ≥ 4-point reduction in WI-NRS pruritus score in participants with WI-NRS pruritus score ≥ 4 at baseline. The WI-NRS is a 10 point scale ranging from 0 ('no itch') to 10 ('worst itch imaginable') the participant experienced in the past 24 hours, with higher scores indicating greater symptoms severity. Results are based on observed data only.

    Time frame: Baseline (Day 1) and Week 2, Week 4, Week 8

  7. Change From Baseline in Psoriasis Symptoms Diary (PSD) Score

    The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The least squares (LS) mean (95% CI) change in PSD total score relative to baseline is presented for each treatment arm, with decreases from baseline indicating symptom improvement.

    Time frame: Baseline (Day 1) and Weeks 4 and 8

07

Results

Posted Oct 18, 2022

Participant flow

Adult participants with chronic plaque psoriasis were enrolled at 43 study sites in the United States and Canada.

Participant flow — Overall Study
MilestoneRoflumilast Cream 0.3%Vehicle Cream
Started290152
Completed264131
Not completed2621
Withdrew: Adverse event12
Withdrew: Lost to follow-up157
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject1011

Outcome measures

PrimaryNumber of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale

The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale
ParticipantsRoflumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale999
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 (Stratification by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.) · Odds ratio (or): 6.59 · 95% CI 3.17 to 13.70Common OR stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
SecondaryTime to Achieve Psoriasis Area Severity Index-50 (PASI-50)

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The time to achieve PASI-50 (defined as a 50% reduction from baseline in PASI score) is presented, and is based on observed data only. Participants are included whether they achieved PASI-50 or not.

Time frame:
From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 124 days)
Reported as:
Median · days
Time to Achieve Psoriasis Area Severity Index-50 (PASI-50)
daysRoflumilast Cream 0.3%Vehicle Cream
Time to Achieve Psoriasis Area Severity Index-50 (PASI-50)30.0 (29.0 to 42.0)NA (71.0 to NA)
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Log Rank · p = <0.0001 · Hazard ratio (hr): 4.207 · 95% CI 3.029 to 5.844HR stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization.
SecondaryNumber of Participants Achieving Psoriasis Area Severity Index-75 (PASI-75)

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Psoriasis Area Severity Index-75 (PASI-75)
ParticipantsRoflumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Psoriasis Area Severity Index-75 (PASI-75)1037
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 10.42 · 95% CI 4.49 to 24.19Common OR stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.

Time frame:
Baseline (Day 1) and Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)
ParticipantsRoflumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)453
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 8.51 · 95% CI 2.45 to 28.86Common OR stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Success in Intertriginous Investigator Global Assessment (I-IGA) Scale Assessment of Disease Severity at Week 8

The number of participants with I-IGA score ≥2 at baseline achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an I-IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline I-IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Success in Intertriginous Investigator Global Assessment (I-IGA) Scale Assessment of Disease Severity at Week 8
ParticipantsRoflumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving Success in Intertriginous Investigator Global Assessment (I-IGA) Scale Assessment of Disease Severity at Week 8325
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0004 · Odds ratio (or): 11.18 · 95% CI 2.33 to 53.68Common OR stratified by pooled study site and baseline IGA per randomization with multiple imputation of missing data.
SecondaryNumber of Participants Achieving I-IGA Score of 'Clear' at Week 8

The number of participants achieving an IGA score of 0 ('clear') at Week 8 is presented (observed data only) for each arm. The I-IGA is a 5-point scale assessing the severity of intertriginous area plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving I-IGA Score of 'Clear' at Week 8
ParticipantsRoflumilast Cream 0.3%Vehicle Cream
Number of Participants Achieving I-IGA Score of 'Clear' at Week 8272
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 15.27 · 95% CI 3.10 to 75.35Common odds ratio stratified by pooled study site and baseline IGA with multiple imputation of missing data.
SecondaryNumber of Participants Achieving Success in Worst Itch Numerical Rating Scale (WI-NRS) Pruritus Score

The number of participants achieving success in WI-NRS is presented. Success is defined as achievement of a ≥ 4-point reduction in WI-NRS pruritus score in participants with WI-NRS pruritus score ≥ 4 at baseline. The WI-NRS is a 10 point scale ranging from 0 ('no itch') to 10 ('worst itch imaginable') the participant experienced in the past 24 hours, with higher scores indicating greater symptoms severity. Results are based on observed data only.

Time frame:
Baseline (Day 1) and Week 2, Week 4, Week 8
Reported as:
Count of participants · Participants
Number of Participants Achieving Success in Worst Itch Numerical Rating Scale (WI-NRS) Pruritus Score
ParticipantsRoflumilast Cream 0.3%Vehicle Cream
Week 29023
Week 412023
Week 814336
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0026 · Odds ratio (or): 2.56 · 95% CI 1.43 to 4.58Common OR stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.93 · 95% CI 2.65 to 9.18Common OR stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.59 · 95% CI 2.07 to 6.23Common OR stratified by pooled study site, baseline IGA, and baseline intertriginous involvement per randomization with multiple imputation of missing data.
SecondaryChange From Baseline in Psoriasis Symptoms Diary (PSD) Score

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The least squares (LS) mean (95% CI) change in PSD total score relative to baseline is presented for each treatment arm, with decreases from baseline indicating symptom improvement.

Time frame:
Baseline (Day 1) and Weeks 4 and 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Psoriasis Symptoms Diary (PSD) Score
score on a scaleRoflumilast Cream 0.3%Vehicle Cream
Week 4-42.7 (-47.7 to -37.7)-16.7 (-22.8 to -10.6)
Week 8-49.3 (-54.8 to -43.7)-22.8 (-29.6 to -16.0)
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.0001 · Mean difference (final values): -26.0 · 95% CI -31.9 to -20.0Site, baseline IGA, baseline intertriginous involvement, and baseline PSD scores were independent variables, multiple imputation used for missing data
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.0001 · Mean difference (final values): -26.5 · 95% CI -33.2 to -19.7Site, baseline IGA, baseline intertriginous involvement, and baseline PSD scores were independent variables, multiple imputation used for missing data

Adverse events

Collected over Up to 124 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Cream 0.3%0/290 (0%)0/290 (0%)0/290 (0%)
Vehicle Cream0/152 (0%)1/152 (0.7%)0/152 (0%)
Most frequent serious events
Most frequent serious events
EventRoflumilast Cream 0.3%Vehicle Cream
Cervical radiculopathyNervous system disorders0/2901/152

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Cream 0.3%Vehicle CreamTotal
Mean46.9 ± 15.0747.1 ± 14.0747.0 ± 14.72
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Cream 0.3%Vehicle CreamTotal
Female11452166
Male176100276
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Cream 0.3%Vehicle CreamTotal
Hispanic or Latino7650126
Not Hispanic or Latino213102315
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roflumilast Cream 0.3%Vehicle CreamTotal
American-Indian or Alaska Native011
Asian20929
Black or African American13922
Native Hawaiian or Other Pacific Islander314
White240126366
Not Reported527
Other8412
More than 1 Race101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roflumilast Cream 0.3%Vehicle CreamTotal
Hispanic or Latino7650126
Not Hispanic or Latino213102315
Not Reported101
Investigator Global Assessment (IGA) Scores at Baseline
Investigator Global Assessment (IGA) Scores at Baseline(Participants)Roflumilast Cream 0.3%Vehicle CreamTotal
0 - Clear000
1 - Almost Clear000
2 - Mild502474
3 - Moderate220118338
4 - Severe201030
Psoriasis Area Severity Index (PASI) Score
Psoriasis Area Severity Index (PASI) Score(score on a scale)Roflumilast Cream 0.3%Vehicle CreamTotal
Mean6.5 ± 3.227.0 ± 3.526.7 ± 3.33
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score(units on a scale)Roflumilast Cream 0.3%Vehicle CreamTotal
Mean5.8 ± 2.616.1 ± 2.755.9 ± 2.66

1 further baseline measures are reported on the registry.

08

Study locations

39 sites
  • Arcutis Biotherapeutics Clinical Site 203
    Scottsdale, Arizona 85255, United States
  • Arcutis Biotherapeutics Clinical Site 239
    Beverly Hills, California 90212, United States
  • Arcutis Biotherapeutics Clinical Site 225
    Encino, California 91436, United States
  • Arcutis Biotherapeutics Clinical Site 220
    San Diego, California 92123, United States
  • Arcutis Biotherapeutics Clinical Site 208
    Santa Monica, California 90404, United States
  • Arcutis Biotherapeutics Clinical Site 215
    Santa Monica, California 90503, United States
  • Arcutis Biotherapeutics Clinical Site 223
    Boynton Beach, Florida 91436, United States
  • Arcutis Biotherapeutics Clinical Site 237
    DeLand, Florida 32720, United States
  • Arcutis Biotherapeutics Clinical Site 228
    Largo, Florida 33770, United States
  • Arcutis Biotherapeutics Clinical Site 201
    North Miami Beach, Florida 33162, United States
  • Arcutis Biotherapeutics Clinical Site 209
    Sweetwater, Florida 33172, United States
  • Arcutis Biotherapeutics Clinical Site 214
    Indianapolis, Indiana 46250, United States
  • Arcutis Biotherapeutics Clinical Site 217
    Louisville, Kentucky 40217, United States
  • Arcutis Biotherapeutics Clinical Site 211
    Lake Charles, Louisiana 70605, United States
  • Arcutis Biotherapeutics Clinical Site 213
    Metairie, Louisiana 70006, United States
  • Arcutis Biotherapeutics Clinical Site 224
    New Orleans, Louisiana 70115, United States
  • Arcutis Biotherapeutics Clinical Site 212
    Detroit, Michigan 48202, United States
  • Arcutis Biotherapeutics Clinical Site 216
    Fridley, Minnesota 55432, United States
  • Arcutis Biotherapeutics Clinical Site 227
    Saint Joseph, Missouri 64506, United States
  • Arcutis Biotherapeutics Clinical Site 219
    Las Vegas, Nevada 89148, United States
  • Arcutis Biotherapeutics Clinical Site 231
    Las Vegas, Nevada 89148, United States
  • Arcutis Biotherapeutics Clinical Site 240
    Reno, Nevada 89703, United States
  • Arcutis Biotherapeutics Clinical Site 236
    Portsmouth, New Hampshire 03801, United States
  • Arcutis Biotherapeutics Clinical Site 222
    Oklahoma City, Oklahoma 73112, United States
  • Arcutis Biotherapeutics Clinical Site 229
    Broomall, Pennsylvania 19008, United States
  • Arcutis Biotherapeutics Clinical Site 233
    Knoxville, Tennessee 37922, United States
  • Arcutis Biotherapeutics Clinical Site 221
    Murfreesboro, Tennessee 37130, United States
  • Arcutis Biotherapeutics Clinical Site 206
    Arlington, Texas 76011, United States
  • Arcutis Biotherapeutics Clinical Site 238
    Houston, Texas 77030, United States
  • Arcutis Biotherapeutics Clinical Site 210
    West Jordan, Utah 84088, United States
  • Arcutis Biotherapeutics Clinical Site 230
    Richmond, Virginia 23220, United States
  • Arcutis Biotherapeutics Clinical Site 207
    Surrey, British Columbia V3R 6A7, Canada
  • Arcutis Biotherapeutics Clinical Site 226
    Surrey, British Columbia V3V0C6, Canada
  • Arcutis Biotherapeutics Clinical Site 232
    Winnepeg, Manitoba R3M 3Z4, Canada
  • Arcutis Biotherapeutics Clinical Site 234
    Fredericton, New Brunswick E3B 1G9, Canada
  • Arcutis Biotherapeutics Clinical Site 205
    Ajax, Ontario L1S 7K8, Canada
  • Arcutis Biotherapeutics Clinical Site 218
    Barrie, Ontario L4M 7G1, Canada
  • Arcutis Biotherapeutics Clinical Site 235
    Toronto, Ontario M4W 2N2, Canada
  • Arcutis Biotherapeutics Clinical Site 204
    Windsor, Ontario N8W 1E6, Canada
09

References and documents

Publications

  • Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. PubMed 36125472 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Nov 2020, 11 months.

Results were first posted in Oct 2022, 1 year 10 months after primary completion. A results delay was requested in Sep 2021.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Dec 26, 2019
StartActual
Dec 17, 2019
Primary completionActual
Nov 23, 2020
CompletionActual
Nov 23, 2020
Results delay requested
Sep 29, 2021
Results first posted
Oct 18, 2022
Last update
Dec 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04211389
Responsible party
Sponsor
First posted
Dec 26, 2019
Start date
Dec 17, 2019
Primary completion
Nov 23, 2020
Completion
Nov 23, 2020
Results posted
Oct 18, 2022
Last update
Dec 7, 2022

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion